BCM
GRCE

Bayesian Capital Management’s Grace Therapeutics GRCE Stock Holding History

Bayesian Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-502
Closed -$46K – 778
2019
Q3 		$46K Buy
+502
New +$46.5K 0.01% 493

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PP
Peconic Partners New York $5.78B AUM 127.23% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bayesian Capital Management's GRCE Position: Q4 2019 in Review

Bayesian Capital Management sold out of Grace Therapeutics (GRCE) in Q4 2019, closing a stake of 502 shares — an estimated $46K sold.

Bayesian Capital Management first reported a position in GRCE in Q3 2019 and held it in 1 quarter. The position peaked at $46K in Q3 2019. 33 funds tracked by Wall St. Rank hold GRCE as of Q4 2019.

  • Bayesian Capital Management reported no remaining Grace Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Bayesian Capital Management sold 502 Grace Therapeutics shares in Q4 2019, an estimated $46K.
  • Bayesian Capital Management first reported a position in Grace Therapeutics in Q3 2019 and held it in 1 quarter.
  • Bayesian Capital Management's Grace Therapeutics position peaked at $46K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2019.

Based on Bayesian Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.